#ASCO26: Kelonia Therapeutics delivers an impressive in vivo CAR-T update
CHICAGO — Eli Lilly in April penned an up to $7 billion deal to buy Kelonia Therapeutics, and now we know why. All 18 multiple myeloma patients who have receive...
CHICAGO — Eli Lilly in April penned an up to $7 billion deal to buy Kelonia Therapeutics, and now we know why. All 18 multiple myeloma patients who have received Kelonia’s in vivo CAR-T therapy ...